Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692933 · ClinicalTrials.gov registry record · Early Phase 1
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
A Early Phase 1 study of Interaction, sponsored by Washington State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06692933: Recruiting Early Phase 1 study of Interaction, sponsored by Washington State University.
NCT06692933 is a Early Phase 1 study of Interaction that is actively recruiting participants, run by Washington State University. The registered enrollment target is 24 participants, above the 21-participant average among 3 other Interaction trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06692933, a Early Phase 1 study of Interaction, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Primary Outcome
Ratio of the area under the plasma concentration vs. time curve of the active metabolite of clopidogrel in the presence to absence of hemp
Conditions Studied
Interventions
- DRUG Cannabidiol in the form of hemp
- DRUG Clopidogrel
Study Locations (1)
Washington
- Washington State University College of Pharmacy and Pharmaceutical Sciences - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
What NCT06692933 shows while recruiting
NCT06692933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, above the 21-participant average among 3 other Interaction trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Interaction appearing as the primary indexed condition, and to 2 interventions - of which Cannabidiol in the form of hemp is the first listed.
NCT06692933 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06692933 about?
NCT06692933 is a clinical study titled "Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel". The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patient...
What is the current status of trial NCT06692933?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-06-20. Estimated completion is 2025-12-31.
What conditions does trial NCT06692933 study?
This clinical trial studies the following conditions: Interaction.
What interventions are being tested in trial NCT06692933?
The interventions under investigation include: Cannabidiol in the form of hemp (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT06692933?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692933 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
RECRUITING · Early Phase 1
-
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
RECRUITING · Early Phase 1
-
The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI